Alto Neuroscience develops drug candidates for psychiatric disorders, using biomarkers found through data analytics to select patients. ANRO reports earnings on Wed, Nov 11, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 17 | HC Wainwright & Co. | Maintained | Buy | |
| Aug 13 | Wedbush | Maintained | Hold | |
| Aug 13 | BTIG | Maintained | Buy | |
| May 18 | Baird | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in ANRO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANRO is in one of them and how their past ANRO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANRO in an article yet. Here's the latest on the wider market.
About Alto Neuroscience
Alto Neuroscience is a pharmaceutical company based in Mountain View, California, that develops drugs for psychiatric disorders. It uses data analytics and machine learning to find biomarkers that can help identify which patients are most likely to benefit from a given treatment. The company is developing its product candidates for conditions including major depressive disorder and schizophrenia, and it has not yet commercialized a drug. Its work is aimed at patients with these conditions and the clinicians who treat them.
- Headquarters
- Mountain View, CA